View Activity

 

A Virtual Reality View:
New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

View Activity

FACULTY

Amy S. Paller, MD
Chair, Department of Dermatology
Director, Skin Biology and Diseases Resource-Based Center
Walter J. Hamlin Professor of Dermatology
Professor Dermatology and Pediatrics
Northwestern Medicine Feinberg School of Medicine
Chicago, IL

Lawrence D. Sher, MD, FAAP, FAAAAI, FACAAI, CPI (ACRP)
Medical Director
Palos Verdes Medical Group
Peninsula Research Associates
Rolling Hills Estates, CA

PROGRAM OVERVIEW

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

TARGET AUDIENCE

This activity is intended for US-based pediatric/adolescent dermatologists, allergists/immunologists and other healthcare professionals who diagnose and manage pediatric/adolescent patients with moderate-to-severe AD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

• Apply updated diagnostic guidance for pediatric and adolescent patients with moderate-to-severe AD and use severity assessments to inform management decisions
• Review the clinical profiles and mechanisms of action of newly approved and emerging systemic/biologic agents for the treatment of pediatric and adolescent patients with moderate-to-severe AD
• Explain the benefits associated with patient centered, team-based shared decision-making approaches for the management of moderate-to-severe AD in children and adolescents

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AD.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY

Amy S. Paller, MD, has nothing to disclose.

Lawrence D. Sher, MD, FAAP, FAAAAI, FACAAI, CPI (ACRP), is on the speakers’ bureau for Regeneron. Dr. Sher has contracted research for Regeneron, Sanofi, Glenmark, Pfizer, Leo, Aimmune, and AstraZeneca.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, Medical Services for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: June 11, 2020

EXPIRATION DATE: June 11, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

View Activity

 

A Virtual Reality View:
New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

View Activity

FACULTY

Amy S. Paller, MD
Chair, Department of Dermatology
Director, Skin Biology and Diseases Resource-Based Center
Walter J. Hamlin Professor of Dermatology
Professor Dermatology and Pediatrics
Northwestern Medicine Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology/Associates of Chicago
Chicago, IL

PROGRAM OVERVIEW

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

TARGET AUDIENCE

This activity is intended for US-based pediatric/adolescent dermatologists, allergists/immunologists and other healthcare professionals who diagnose and manage pediatric/adolescent patients with moderate-to-severe AD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

• Apply updated diagnostic guidance for pediatric and adolescent patients with moderate-to-severe AD and use severity assessments to inform management decisions
• Review the clinical profiles and mechanisms of action of newly approved and emerging systemic/biologic agents for the treatment of pediatric and adolescent patients with moderate-to-severe AD
• Explain the benefits associated with patient centered, team-based shared decision-making approaches for the management of moderate-to-severe AD in children and adolescents

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AD.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY

Amy S. Paller, MD, has nothing to disclose.

Peter A. Lio, MD, has received grants as an investigator and/or honoraria for lecturing, and/or consulting fees from: Eli Lilly, UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, La Roche Posay/L’Oreal, Pierre-Fabre, Johnson & Johnson, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Franklin Bioscience/Altus Labs, Verrica, TopMD, Arbonne, Burt’s Bees, and the National Eczema Association.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, Medical Services for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: June 11, 2020

EXPIRATION DATE: June 11, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

View Activity

 

Infographic Virtual Preceptorship: Multidisciplinary Care of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

View Activity

 

Program Toolkit

Download Your Complimentary Poster

FACULTY

Amy S. Paller, MD
Chair, Department of Dermatology
Director, Skin Biology and Diseases Resource-Based Center
Walter J. Hamlin Professor of Dermatology
Professor Dermatology and Pediatrics
Northwestern Medicine Feinberg School of Medicine
Chicago, IL

PROGRAM OVERVIEW

This enduring activity will cover HCPs involved in the management of pediatric and adolescent patients with atopic dermatitis.

TARGET AUDIENCE

This activity is intended for dermatologists, pediatric dermatologists, pediatricians, primary care physicians, and other healthcare professionals involved in the management of pediatric and adolescent patients with atopic dermatitis.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

• Develop treatment plans for the management of atopic dermatitis in pediatric and adolescent patients that incorporate guideline recommendations, evidence from clinical trials, and patient-specific factors
• Identify patients who would benefit from treatment intensification based on disease severity, failure of prior therapy, and comorbid conditions
• Incorporate strategies into clinical practice that encourage patient-centered and multidisciplinary care of atopic dermatitis

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 0.50 AMA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AD.

Credits: 0.50 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Conference Complete Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.50 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Amy S. Paller, MD, served as consultant to Almirall, Amgen, Asana, Boehringer-Ingelheim, Castle Creek, Celgene, Dermavant, Dermira, Eli Lilly, Exicure, Forte, Galderma, Lenus, Leo, Meda Corp., Meiji Seika, Novan, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, and Sol Gel.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: October 23, 2020

EXPIRATION DATE: October 23, 2021

Privacy and confidentiality policy statement information is available at www.medlearninggroup.com/privacy-policy/

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

Online Situation Room: Improving the Ability to Diagnose and Treat Atopic Dermatitis in Clinical Practice A part of the THRIVE – Atopic Dermatitis Initiative

View Activity

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

---

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Diana Tommasi, Director of Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

---

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

---

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.

---

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: November 4, 2020

EXPIRATION DATE: November 4, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Med learning group will be glad to assist you with any special needs. Please contact Med Learning Group at any time at info@medlearninggroup.com.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

The Evolving Role of Systemic Therapies in the Management of Atopic Dermatitis: Key Principles in Patient Care and Education

VIEW ACTIVITY

FACULTY

Peter Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH
Professor of Dermatology
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

PROGRAM OVERVIEW

This online activity will review evidence-based approaches to the diagnosis and management of atopic dermatitis (AD), in addition to associated quality of life issues and adverse events associated with disease and treatment.

TARGET AUDIENCE

This activity is intended for pediatricians, dermatologists, pediatric dermatologists, primary care physicians, and other healthcare professionals involved in the management of pediatric and adolescent patients with atopic dermatitis.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Apply evidence-based approaches to diagnose, assess, and manage moderate-to-severe atopic dermatitis in pediatric and adolescent patients
• Assess the physical, psychosocial, and developmental impact of atopic dermatitis on patients’ quality of life when selecting therapy options and evaluating therapeutic outcomes
• Recognize and manage the adverse events associated with systemic and topical therapies for the management of atopic dermatitis in pediatric and adolescent patients

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of pediatric and adolescent patients with atopic dermatitis.
Credits: 1.25 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Peter Lio, MD has received grants as an investigator and/or honoraria for lecturing, and/or consulting fees from: Eli Lilly, UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, La Roche Posay/L’Oreal, Pierre-Fabre, Johnson & Johnson, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Franklin Bioscience/Altus Labs, Verrica, TopMD, Arbonne, Burt’s Bees, and the National Eczema Association.

Jonathan I. Silverberg, MD, PhD, MPH is consultant and/or advisory board member for Abbvie, Afyx, Arena, Asana, Bluefin, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi, and is on the speaker’s bureau for Sanofi-Regeneron.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
Chris Drury, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete the pre-and-post survey and evaluation.

Participants will receive their certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: January 13, 2021

EXPIRATION DATE: January 13, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY